Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves

Department of Medicine (Cardiology), Tufts University School of Medicine, Boston, Massachusetts 02111, USA.

This review examines the results of vasodilator therapy in patients with chronic regurgitant lesions of the aortic and mitral valves. The analysis includes those studies which provide data on hemodynamic measurements, left ventricular systolic function, ventricular volumes and regurgitant flow. In patients with chronic aortic or mitral regurgitation, the short-term administration of nitroprusside, hydralazine, nifedipine or an angiotensin-converting enzyme (ACE) inhibitor produces salutary hemodynamic effects. The major difference in the response to combined preload and afterload reduction (i.e., nitroprusside) in patients with aortic versus mitral regurgitation was that forward stroke volume generally increased and ejection fraction remained unchanged in mitral regurgitation, whereas ejection fraction generally increased and forward stroke volume remained unchanged in aortic regurgitation. These observations suggest that a reciprocal relation between regurgitant and forward flow characterizes the response to preload and afterload reduction in mitral regurgitation (through a preload-dependent dynamic regurgitant orifice), whereas correction of afterload mismatch dominates the response in aortic regurgitation. In studies of long-term vasodilator therapy in patients with chronic aortic regurgitation, a reduction in left ventricular volumes and regurgitant fraction, with or without an increase in ejection fraction, has been observed during treatment with hydralazine, nifedipine and ACE inhibitors. Patients with the largest, sickest hearts generally benefit the most from treatment with vasoactive drugs. Nonetheless, favorable ventricular remodeling has been reported in asymptomatic patients, and long-term nifedipine use has delayed the need for operation in asymptomatic patients with chronic aortic regurgitation. For patients with chronic mitral regurgitation, definition of the etiology of the lesion is a prerequisite for choosing appropriate therapy. Excluding patients with obstructive hypertrophic cardiomyopathy and mitral valve prolapse, and some with fixed-orifice (i.e., rheumatic) mitral regurgitation, the signal importance of preload reduction suggests that the preferred long-term therapy for symptomatic chronic mitral regurgitation is an ACE inhibitor. There are no long-term studies that support the use of vasodilator therapy in asymptomatic patients with chronic mitral regurgitation.

This article has been cited by other articles:

				D. H. J. Elder, L. Wei, B. R. Szwejkowski, R. Libianto, A. Nadir, M. Pauriah, S. Rekhraj, T. K. Lim, J. George, A. Doney, et al. The Impact of Renin-Angiotensin-Aldosterone System Blockade on Heart Failure Outcomes and Mortality in Patients Identified to Have Aortic Regurgitation: A Large Population Cohort Study J. Am. Coll. Cardiol., November 8, 2011; 58(20): 2084 - 2091. [Abstract] [Full Text] [PDF]

				P. A. Grayburn The Importance of Regurgitant Orifice Shape in Mitral Regurgitation J. Am. Coll. Cardiol. Img., October 1, 2011; 4(10): 1097 - 1099. [Full Text] [PDF]

				O. Franzen, J. van der Heyden, S. Baldus, M. Schluter, W. Schillinger, C. Butter, R. Hoffmann, R. Corti, G. Pedrazzini, M. J. Swaans, et al. MitraClip(R) therapy in patients with end-stage systolic heart failure Eur J Heart Fail, May 1, 2011; 13(5): 569 - 576. [Abstract] [Full Text] [PDF]

				O. Franzen, S. Baldus, V. Rudolph, S. Meyer, M. Knap, D. Koschyk, H. Treede, A. Barmeyer, J. Schofer, A. Costard-Jackle, et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction Eur. Heart J., June 1, 2010; 31(11): 1373 - 1381. [Abstract] [Full Text] [PDF]

				D. Detaint, B. Iung, L. Lepage, D. Messika-Zeitoun, G. Baron, P. Tornos, C. Gohlke-Barwolf, and A. Vahanian Management of asymptomatic patients with severe non-ischaemic mitral regurgitation. Are practices consistent with guidelines? Eur J Cardiothorac Surg, November 1, 2008; 34(5): 937 - 942. [Abstract] [Full Text] [PDF]

				2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]

				R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., September 23, 2008; 52(13): e1 - e142. [Full Text] [PDF]

				P A Grayburn How to measure severity of mitral regurgitation Postgrad. Med. J., August 1, 2008; 84(994): 395 - 402. [Full Text] [PDF]

				P. A Grayburn How to measure severity of mitral regurgitation Heart, March 1, 2008; 94(3): 376 - 383. [Full Text] [PDF]

				M. Mirabel, B. Iung, G. Baron, D. Messika-Zeitoun, D. Detaint, J.-L. Vanoverschelde, E. G. Butchart, P. Ravaud, and A. Vahanian What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur. Heart J., June 1, 2007; 28(11): 1358 - 1365. [Abstract] [Full Text] [PDF]

				R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]

				R. R. Brandt, C. Reiner, R. Arnold, J. Sperzel, H. F. Pitschner, and C. W. Hamm Contractile response and mitral regurgitation after temporary interruption of long-term cardiac resynchronization therapy Eur. Heart J., January 2, 2006; 27(2): 187 - 192. [Abstract] [Full Text] [PDF]

				R. Bekeredjian and P. A. Grayburn Valvular Heart Disease: Aortic Regurgitation Circulation, July 5, 2005; 112(1): 125 - 134. [Abstract] [Full Text] [PDF]

				A. Chockalingam, S. Venkatesan, S. Dorairajan, V. Chockalingam, T. Subramaniam, V. Jaganathan, S. Elangovan, R. Alagesan, G. Gnanavelu, and A. S. Arul Safety and Efficacy of Enalapril in Multivalvular Heart Disease with Significant Mitral Stenosis--SCOPE-MS Angiology, March 1, 2005; 56(2): 151 - 158. [Abstract] [PDF]

				S. de Denus, C. Pharand, and D. R. Williamson Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone Chest, February 1, 2004; 125(2): 652 - 668. [Abstract] [Full Text] [PDF]

				W. H. Gaasch and E. C. Schick Symptoms and left ventricular size and function in patients with chronic aortic regurgitation J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1325 - 1328. [Full Text] [PDF]

				B. Iung Management of ischaemic mitral regurgitation Heart, April 1, 2003; 89(4): 459 - 464. [Full Text] [PDF]

				C. M Otto Timing of surgery in mitral regurgitation Heart, January 1, 2003; 89(1): 100 - 105. [Full Text] [PDF]

				Y J Kim, M Jones, T Shiota, H Tsujino, J X Qin, F Bauer, M Sitges, J Kwan, L A Cardon, A D Zetts, et al. Effect of load alterations on the effective regurgitant orifice area in chronic aortic regurgitation Heart, October 1, 2002; 88(4): 397 - 400. [Abstract] [Full Text] [PDF]

				J.-F. Avierinos, B. J. Gersh, L. J. Melton III, K. R. Bailey, C. Shub, R. A. Nishimura, A. J. Tajik, and M. Enriquez-Sarano Natural History of Asymptomatic Mitral Valve Prolapse in the Community Circulation, September 10, 2002; 106(11): 1355 - 1361. [Abstract] [Full Text] [PDF]

				B. Iung, C. Gohlke-Barwolf, P. Tornos, C. Tribouilloy, R. Hall, E. Butchart, and A. Vahanian Recommendations on the management of the asymptomatic patient with valvular heart disease Eur. Heart J., August 2, 2002; 23(16): 1253 - 1266. [PDF]

				F. Grigioni, J.-F. Avierinos, L. H. Ling, C. G. Scott, K. R. Bailey, A. J. Tajik, R. L. Frye, and M. Enriquez-Sarano Atrial fibrillation complicating the course of degenerative mitral regurgitation: Determinants and long-term outcome J. Am. Coll. Cardiol., July 3, 2002; 40(1): 84 - 92. [Abstract] [Full Text] [PDF]

				G. J. Perry, C.-C. Wei, G. H. Hankes, S. R. Dillon, P. Rynders, R. Mukherjee, F. G. Spinale, and L. J. Dell'Italia Angiotensin II receptor blockade does not improve left ventricular function andremodeling in subacute mitral regurgitation in the dog J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1374 - 1379. [Abstract] [Full Text] [PDF]

				W. H. Gaasch and G. P. Aurigemma Inhibition of therenin-angiotensin systemand the left ventricularadaptation to mitral regurgitation J. Am. Coll. Cardiol., April 17, 2002; 39(8): 1380 - 1383. [Full Text] [PDF]

				N A Boon and P Bloomfield The medical management of valvar heart disease Heart, April 1, 2002; 87(4): 395 - 400. [Full Text] [PDF]

				D. L. Willett, S. A. Hall, M. E. Jessen, M. A. Wait, and P. A. Grayburn Assessment of aortic regurgitation by transesophageal color Doppler imaging of the vena contracta: validation against an intraoperative aortic flow probe J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1450 - 1455. [Abstract] [Full Text] [PDF]

				M. Enriquez-Sarano, A.-J. Basmadjian, A. Rossi, K. R. Bailey, J. B. Seward, and A. J. Tajik Progression of mitral regurgitation: A prospective Doppler echocardiographic study J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1137 - 1144. [Abstract] [Full Text] [PDF]

				K. S. Dujardin, M. Enriquez-Sarano, H. V. Schaff, K. R. Bailey, J. B. Seward, and A. J. Tajik Mortality and Morbidity of Aortic Regurgitation in Clinical Practice : A Long-Term Follow-Up Study Circulation, April 13, 1999; 99(14): 1851 - 1857. [Abstract] [Full Text] [PDF]

				C. M. Tribouilloy, M. Enriquez-Sarano, H. V. Schaff, T. A. Orszulak, K. R. Bailey, A. J. Tajik, and R. L. Frye Impact of Preoperative Symptoms on Survival After Surgical Correction of Organic Mitral Regurgitation : Rationale for Optimizing Surgical Indications Circulation, January 26, 1999; 99(3): 400 - 405. [Abstract] [Full Text] [PDF]

				A. M. Kizilbash, D. L. Willett, M. E. Brickner, S. K. Heinle, and P. A. Grayburn Effects of afterload reduction on vena contracta width in mitral regurgitation J. Am. Coll. Cardiol., August 1, 1998; 32(2): 427 - 431. [Abstract] [Full Text] [PDF]